Drug
ABO2203 Injection
ABO2203 Injection is a pharmaceutical drug with 2 clinical trials. Currently 2 active trials ongoing.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(100%)
Phase Distribution
Ph early_phase_1
1
50%
Ph phase_1
1
50%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Early Phase 1First-in-human
1(50.0%)
Phase 1Safety & dosage
1(50.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
2
all time
Status Distribution
Active(2)
Detailed Status
Recruiting2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
Early Phase 1
Trials by Phase
Early Phase 11 (50.0%)
Phase 11 (50.0%)
Trials by Status
recruiting2100%
Recent Activity
2 active trials
Showing 2 of 2
recruitingearly_phase_1
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
NCT06747156
recruitingphase_1
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT07072169
Clinical Trials (2)
Showing 2 of 2 trials
NCT06747156Early Phase 1
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
NCT07072169Phase 1
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2